• Home
  • E-submission
  • Sitemap
  • Contact us
  • Search
  • Advanced Search
Intest Res Search

CLOSE

‘Intestinal Research’ (Intest Res) is the joint official publication of the Asian Organization for Crohn's and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn's Foundation (India) (CCF, india).
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance.As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines.

Review

December 1, 2020


Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Intest Res. 2021;19(4):360-364.

Immune checkpoint inhibitor therapies such as ipilimumab, are increasingly being used as a treatment option for a variety of cancers, including metastatic melanoma and have demonstrated effectively a prolonged survival....

Review

November 25, 2020


Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intest Res. 2021;19(4):365-378.

Over recent years, inflammatory bowel diseases have become an issue of increased attention in daily clinical practice, due to both a rising incidence and improved imaging capability in detection. In...

Review

November 6, 2020


An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.
Intest Res. 2021;19(4):379-385.

In late 2019, an outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initiated in Wuhan, Hubei province, China. The major clinical symptoms described for coronavirus disease...

Original Article

December 1, 2020


Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Intest Res. 2021;19(4):386-397.

Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data...

Original Article

November 20, 2020


Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, et al.
Intest Res. 2021;19(4):398-407.

Background/Aims: Information on pediatric inflammatory bowel disease (PIBD) and very early onset IBD (VEOIBD) are sparse in India, where IBD is emerging. We aimed to evaluate characteristics of VEOIBD and...

Original Article

November 20, 2020


Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, et al.
Intest Res. 2021;19(4):408-418.

Background/Aims: Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up...

Original Article

November 10, 2020


Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, et al.
Intest Res. 2021;19(4):419-429.

Background/Aims: Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to severe ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan....

Original Article

November 9, 2020


Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, et al.
Intest Res. 2021;19(4):430-437.

Background/Aims: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract. Some patients with this condition have been reported to present with immunoglobulin A nephropathy (IgAN), a renal...

Original Article

November 6, 2020


High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, et al.
Intest Res. 2021;19(4):438-447.

Background/Aims: Predictors of short-term outcome of intravenous (IV) steroid therapy in acute severe ulcerative colitis (ASUC) have been well described, but the impact of cytomegalovirus (CMV) infection as a predictor...

Original Article

August 18, 2020


Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, et al.
Intest Res. 2021;19(4):448-460.

Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy...

Original Article

August 18, 2020


Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, et al.
Intest Res. 2021;19(4):461-467.

Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs)...
Current Issue
Volume 19(4); Oct 2021
Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models
Emiko Mizoguchi, Daren Low, Yui Ezaki, et al.
Intest Res. 2020;18(2):151-167.

Review

Epub April 20, 2020
Novel biomarkers for the diagnosis and prognosis of colorectal cancer
Hyung-Hoon Oh, Young-Eun Joo
Intest Res. 2020;18(2):168-183.

Review

Epub November 30, 2019
Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases
Jung Min Kim, Jae Hee Cheon
Intest Res. 2020;18(3):249-264.

Review

Epub April 18, 2020
The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease
Chan Hyung Lee, Hyuk Yoon, Dong Jun Oh, et al.
Intest Res. 2020;18(1):79-84.

Original Article

Epub January 30, 2020
Fibrostenotic strictures in Crohn’s disease
Jun Hwan Yoo, Stefan Holubar, Florian Rieder
Intest Res. 2020;18(4):379-401.

Review

Epub April 10, 2020
Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases
Julajak Limsrivilai, Nonthalee Pausawasdi
Intest Res. 2021;19(1):21-32.

Review

Epub April 22, 2020
5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
Shinta Mizuno, Keiko Ono, Yohei Mikami, et al.
Intest Res. 2020;18(1):69-78.

Original Article

Epub January 30, 2020
Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study
Jamilya Kaibullayeva, Aliya Ualiyeva, Ainash Oshibayeva, et al.
Intest Res. 2020;18(4):430-437.

Original Article

Epub September 29, 2020
Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease
Antigony Mitselou, Vasileios Grammeniatis, Anna Varouktsi, et al.
Intest Res. 2020;18(1):115-120.

Original Article

Epub January 30, 2020
Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Sanchit Sharma, Arti Gupta, Saurabh Kedia, et al.
Intest Res. 2021;19(3):291-300.

Original Article

Epub May 26, 2020
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
Sang Hyoung Park, Jae Cheol Park, Milan Lukas, et al.
Intest Res. 2020;18(1):34-44.

Review

Epub January 30, 2020
Differentiation of fibrotic and inflammatory component of Crohn’s disease-associated strictures
Jordi Rimola, Nunzia Capozzi
Intest Res. 2020;18(2):144-150.

Review

Epub April 20, 2020
The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, et al.
Intest Res. 2021;19(1):62-70.

Original Article

Epub May 8, 2020
Capsule endoscopy in inflammatory bowel disease: when and how
Ida Hilmi, Taku Kobayashi
Intest Res. 2020;18(3):265-274.

Review

Epub July 7, 2020
Update of endoscopic management of Crohn’s disease strictures
Akshay Pokala, Bo Shen
Intest Res. 2020;18(1):1-10.

Review

Epub January 30, 2020
Pediatric to adult inflammatory bowel disease transition: the Asian experience
Bernice Tan, David Ong
Intest Res. 2020;18(1):11-17.

Review

Epub January 30, 2020
Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice
Jin Imai, Takashi Yahata, Hitoshi Ichikawa, et al.
Intest Res. 2020;18(2):219-228.

Original Article

Epub February 17, 2020
Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver
Ashish Agarwal, Alka Singh, Wajiha Mehtab, et al.
Intest Res. 2021;19(1):106-114.

Original Article

Epub April 22, 2020
NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
Katsuyoshi Matsuoka
Intest Res. 2020;18(3):275-281.

Review

Epub June 3, 2020
Melatonin in the colon modulates intestinal microbiota in response to stress and sleep deprivation
Young Sook Park, Soo Hyung Kim, Jong Won Park, et al.
Intest Res. 2020;18(3):325-336.

Original Article

Epub June 23, 2020
Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Sahil Khanna
Intest Res. 2021;19(3):265-274.

Review

Epub August 18, 2020
Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion
Kenji Watanabe
Intest Res. 2020;18(4):347-354.

Review

Epub October 26, 2020
An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.
Intest Res. 2021;19(4):379-385.

Review

Epub November 6, 2020
Quality of life in inflammatory bowel diseases: it is not all about the bowel
Ronald Keller, Nazar Mazurak, Laura Fantasia, et al.
Intest Res. 2021;19(1):45-52.

Original Article

Epub February 27, 2020
Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice
Yan Chen, Qiao Yu, Francis A. Farraye, et al.
Intest Res. 2021;19(3):332-340.

Original Article

Epub June 2, 2020
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, et al.
Intest Res. 2020;18(1):18-33.

Review

Epub January 30, 2020
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
Masayuki Saruta, Dong Il Park, Young-Ho Kim, et al.
Intest Res. 2020;18(1):45-55.

Original Article

Epub January 30, 2020
Comparing histamine intolerance and non-clonal mast cell activation syndrome
Nevio Cimolai
Intest Res. 2020;18(1):134-135.

Letters to the Editor

Epub January 30, 2020
Histologically confirmed upper gastrointestinal Crohn’s disease: is it rare or are we just not searching hard enough?
Omar Ibrahim Saadah, Kholoud Bakur Fallatah, Cedric Baumann, et al.
Intest Res. 2020;18(2):210-218.

Original Article

Epub February 7, 2020
Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
Ajit Sood, Arshdeep Singh, Ritu Sudhakar, et al.
Intest Res. 2020;18(2):184-191.

Original Article

Epub February 25, 2020
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD
ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2022 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next
Close layer
prev next